Ultragenyx UK

Allopurinol is a small-molecule oral therapeutic being investigated by Ultragenyx UK Limited for leishmaniasis treatment, currently in Phase 2 development with a completed status as of June 2024. Allopurinol is a well-established xanthine oxidase inhibitor with a long regulatory history; however, the specific mechanism of action and molecular target for this leishmaniasis indication are not yet disclosed. The program, identified as internal code 199/11679, represents a potential repurposing strategy for an existing drug class into a parasitic disease indication.

The development program is supported by clinical trial NCT00004755. Ultragenyx's strategy appears focused on evaluating allopurinol's efficacy in leishmaniasis, a neglected tropical disease with significant unmet medical need in endemic regions. The Phase 2 program reached its latest milestone on 24 June 2005, with no subsequent milestone disclosures available. Peak sales projections, regulatory timelines, and next development milestones have not been disclosed.

Allopurinol itself maintains extensive regulatory approval across major markets: approved in the United States under multiple generic applications, approved in Australia with multiple PBS listings, and previously authorized in the European Union (though withdrawn from one combination product). The drug is manufactured by numerous generic suppliers globally, reflecting its established market position for its traditional indications.

Leishmaniasis remains a significant public health burden in tropical and subtropical regions, with limited treatment options and emerging drug resistance concerns. The disease affects millions annually, particularly in resource-limited settings where treatment accessibility and tolerability are critical factors. Repurposing an established, well-tolerated oral agent like allopurinol could address unmet needs in leishmaniasis treatment by offering a potentially safer, more accessible, and cost-effective alternative to existing therapies.

Commercially, leishmaniasis represents a neglected tropical disease market with limited commercial incentives, yet significant humanitarian and public health importance. Successful development could position Ultragenyx in the neglected tropical disease space and potentially attract regulatory incentives such as orphan drug designations or priority review pathways. The competitive landscape for leishmaniasis treatment includes limited approved options, creating opportunity for differentiated therapies.

The program's completion status as of 2005 suggests either transition to later-stage development, discontinuation, or transition to a different development pathway. The extended timeline since the last disclosed milestone (19 years) indicates either dormant program status or lack of public disclosure of recent activities. Market relevance depends on comparative efficacy, safety, and tolerability data relative to existing leishmaniasis treatments, which remain undisclosed in available sources.

Drug Class: Xanthine oxidase inhibitor (established therapeutic class)

Modality: Small molecule

Route of Administration: Oral

Therapeutic Classification: Musculo-skeletal system (ATC M04) — though indication is leishmaniasis, a parasitic disease

Mechanism of Action: Not yet disclosed for leishmaniasis indication

Molecular Target: Not yet disclosed for leishmaniasis indication

Related Therapies: Allopurinol has established approvals for gout and hyperuricemia management. The repurposing for leishmaniasis represents investigation of off-label or novel indication.

Regulatory History: Allopurinol brand ALLOPURINOL SANDOZ is approved in Australia (PBS listed since 1992), approved in the United States under 31 distinct generic applications and original NDAs, and previously authorized in the European Union. Multiple manufacturers produce generic formulations globally.

Patent Status: Not disclosed; allopurinol is a long-established chemical entity with expired patent protection for traditional indications.

United States (FDA): Allopurinol is approved as a generic drug under 31 distinct applications (NDAs and ANDAs), with multiple manufacturers authorized including Abbott, Accord Healthcare, Aurobindo Pharma, Mylan, Sandoz, Sun Pharmaceutical, and others. Original NDAs include NDA016084, NDA018241, NDA018297, NDA018785, NDA018832, NDA018877, and NDA209203.

European Union (EMA): Allopurinol was previously authorized; one combination product (DUZALLO, EMA/H/C/004412, MAH Grunenthal GmbH) was authorized on 31 July 2019 but subsequently withdrawn.

Australia (TGA): Allopurinol SANDOZ is approved with multiple PBS listings (codes 13358C, 13575L, 2600W, 2604C). Multiple sponsors including Alphapharm, Apotex, Arrow Pharma, Avallon Pharmaceuticals, and Sandoz hold approvals with first listed dates from 1 December 1992 onwards.

China (NMPA): Clinical trial NCT02797028 indicates ongoing clinical trial activity in China; regulatory approval status not yet disclosed.

Leishmaniasis Indication: Regulatory pathway, approval status, and timelines for the leishmaniasis indication are not yet disclosed.

Program Status Ambiguity: The Phase 2 program's completion status as of June 2005 with no subsequent milestone disclosures over 19 years suggests either: (1) program dormancy or discontinuation, (2) transition to alternative development pathways not publicly disclosed, or (3) development conducted under non-disclosure agreements. The lack of recent clinical trial registrations or publications limits visibility into current program status.

Strategic Implications: Ultragenyx's involvement in a neglected tropical disease program represents potential portfolio diversification into high-unmet-need, lower-commercial-return therapeutic areas. Success could establish capabilities in parasitic disease development and potentially attract regulatory incentives (orphan drug designation, priority review). However, the extended dormancy period raises questions about commercial viability or technical challenges encountered.

Competitive Positioning: Allopurinol's established safety profile, oral bioavailability, and extensive manufacturing infrastructure provide potential advantages if efficacy in leishmaniasis is demonstrated. However, competitive differentiation versus existing leishmaniasis therapies remains unestablished without disclosed efficacy and safety data.

Future Catalysts: Potential catalysts include: (1) publication of Phase 2 trial results, (2) advancement to Phase 3 development, (3) regulatory designation grants, (4) partnership announcements, (5) clinical trial registration updates. The absence of expected next milestone disclosures limits near-term catalyst visibility.